Data / Drug companies / Novartis Pharmaceuticals Corporation
Novartis Pharmaceuticals Corporation: 190 products in the FDA NDC directory, labeler code 0078
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Novartis Pharmaceuticals Corporation (labeler code 0078) lists 190 products in the FDA National Drug Code Directory, covering 55 finished drugs by generic name. By type: 163 prescription drugs, 25 bulk ingredients. Its main marketing category is new drug applications (NDA). The newest product started marketing on September 30, 2025.
The request: Watch Novartis Pharmaceuticals Corporation (FDA labeler code 0078): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 0078
- Products in commercial distribution
- 190
- Packages
- 223
- Finished drugs by generic name
- 55
- Prescription products
- 163
- Over the counter products
- 0
- Controlled substance products
- Schedule II 8
- Flagged as original packager
- 118 of 118 products that carry the flag
- Started marketing in the last 12 months
- 0
- Products with a marketing end date set
- 13
- Earliest marketing start
- March 11, 1968
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 143 | 75.3% |
| Bulk ingredients | 25 | 13.2% |
| Biologics (BLA) | 12 | 6.3% |
| Drugs for further processing | 10 | 5.3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 163 | 85.8% |
| Bulk ingredients | 25 | 13.2% |
| Cellular therapies | 2 | 1.1% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Everolimus | 11 | 15 |
| Deferasirox | 9 | 21 |
| Dexmethylphenidate hydrochloride | 8 | 17 |
| Alpelisib | 7 | 1 |
| Sacubitril and valsartan | 7 | 29 |
| Valsartan | 7 | 38 |
| Cyclosporine | 6 | 24 |
| Octreotide acetate | 6 | 11 |
| Eltrombopag olamine | 6 | 7 |
| Valsartan and hydrochlorothiazide | 5 | 21 |
| Amlodipine valsartan and hydrochlorothiazide | 5 | 1 |
| Carbamazepine | 5 | 52 |
| Oxcarbazepine | 4 | 46 |
| Secukinumab | 4 | 1 |
| Amlodipine besylate and valsartan | 4 | 1 |
| Imatinib mesylate | 3 | 17 |
| Trametinib | 3 | 1 |
| Rivastigmine | 3 | 11 |
| Siponimod | 3 | 1 |
| Asciminib | 3 | 1 |
| Dabrafenib | 3 | 1 |
| Ribociclib | 3 | 1 |
| Nilotinib | 3 | 10 |
| Mycophenolic acid | 2 | 16 |
| Basiliximab | 2 | 1 |
| Tisagenlecleucel | 2 | 1 |
| Fingolimod hcl | 2 | 2 |
| Capmatinib | 2 | 1 |
| Canakinumab | 1 | 1 |
| Tobramycin and dexamethasone | 1 | 14 |
| Neomycin sulfate, polymyxin b sulfate and dexamethasone | 1 | 11 |
| Lifitegrast | 1 | 3 |
| Remibrutinib | 1 | 1 |
| Topotecan hydrochloride | 1 | 4 |
| Betaxolol hydrochloride | 1 | 3 |
| Nepafenac | 1 | 2 |
| Atrasentan | 1 | 1 |
| Iptacopan | 1 | 1 |
| Lutetium lu 177 vipivotide tetraxetan | 1 | 1 |
| Letrozole | 1 | 17 |
| Deferoxamine mesylate | 1 | 6 |
| Rydapt | 1 | 1 |
| Lapatinib | 1 | 4 |
| Triclabendazole | 1 | 1 |
| Ofatumumab | 1 | 1 |
| Kit for the preparation of gallium ga 68 gozetotide | 1 | 1 |
| Tobramycin | 1 | 41 |
| Brolucizumab | 1 | 1 |
| Triamcinolone acetonide | 1 | 77 |
| Clofazimine | 1 | 1 |
| Artemether and lumefantrine | 1 | 1 |
| Ceritinib | 1 | 1 |
| Crizanlizumab | 1 | 1 |
| Inclisiran | 1 | 1 |
| Pazopanib hydrochloride | 1 | 3 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 54 | 28.4% |
| Tablet | 27 | 14.2% |
| Powder | 13 | 6.8% |
| Liquid | 12 | 6.3% |
| Injection, solution | 9 | 4.7% |
| Capsule, extended release | 8 | 4.2% |
| Capsule | 8 | 4.2% |
| Tablet, for suspension | 7 | 3.7% |
| Capsule, liquid filled | 6 | 3.2% |
| Kit | 5 | 2.6% |
| Injection | 5 | 2.6% |
| Granule | 4 | 2.1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Rhapsido | 0078-1483 | Tablet | New drug applications (NDA) | September 30, 2025 |
| Vanrafia | 0078-1420 | Tablet, film coated | New drug applications (NDA) | April 2, 2025 |
| Triesence | 0078-0897 | Injection, suspension | New drug applications (NDA) | October 1, 2024 |
| Vijoice | 0078-1175 | Granule | New drug applications (NDA) | April 24, 2024 |
| Entresto | 0078-1238 | Pellet | New drug applications (NDA) | April 12, 2024 |
| Entresto | 0078-1231 | Pellet | New drug applications (NDA) | April 12, 2024 |
| Tislelizumab | 0078-1511 | Liquid | Bulk ingredients | March 14, 2024 |
| Iptacopan | 0078-1455 | Powder | Bulk ingredients | December 5, 2023 |
| Fabhalta | 0078-1189 | Capsule | New drug applications (NDA) | December 5, 2023 |
| Cosentyx | 0078-1168 | Injection, solution, concentrate | Biologics (BLA) | October 6, 2023 |
| Adalimumab-adaz | 0078-1329 | Liquid | Bulk ingredients | July 1, 2023 |
| Mekinist | 0078-1161 | Powder, for solution | New drug applications (NDA) | March 16, 2023 |
| Tafinlar | 0078-1154 | Tablet, for suspension | New drug applications (NDA) | March 16, 2023 |
| Alpelisib | 0078-1364 | Powder | Bulk ingredients | April 5, 2022 |
| Vijoice | 0078-1035 | Kit | New drug applications (NDA) | April 5, 2022 |
| Vijoice | 0078-1028 | Tablet | New drug applications (NDA) | April 5, 2022 |
| Vijoice | 0078-1021 | Tablet | New drug applications (NDA) | April 5, 2022 |
| Locametz | 0078-1224 | Injection, powder, lyophilized, for solution | New drug applications (NDA) | March 23, 2022 |
| Pluvicto | 0078-1217 | Injection, solution | New drug applications (NDA) | March 23, 2022 |
| Leqvio | 0078-1000 | Injection, solution | New drug applications (NDA) | December 22, 2021 |
| Scemblix | 0078-1196 | Tablet, film coated | New drug applications (NDA) | October 29, 2021 |
| Scemblix | 0078-1098 | Tablet, film coated | New drug applications (NDA) | October 29, 2021 |
| Scemblix | 0078-1091 | Tablet, film coated | New drug applications (NDA) | October 29, 2021 |
| Ferumoxytol | 0078-1357 | Liquid | Bulk ingredients | July 15, 2021 |
| Ofatumumab | 0078-1539 | Liquid | Bulk ingredients | August 20, 2020 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.